These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 445500)

  • 21. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.
    de Palo GM; de Lena M; Di Re F; Luciani L; Valagussa P; Bonadonna G
    Surg Gynecol Obstet; 1975 Dec; 141(6):899-902. PubMed ID: 1103333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria].
    Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K
    Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Importance of serum acid phosphatase for the prognosis of prostatic carcinoma].
    Breitwieser P; Nöske HD
    Z Urol Nephrol; 1971 Apr; 64(4):249-56. PubMed ID: 5094006
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostatic acid phosphatase measurement: its role in detection and management of prostatic cancer.
    Ann N Y Acad Sci; 1982; 390():1-145. PubMed ID: 6953920
    [No Abstract]   [Full Text] [Related]  

  • 25. A radioimmunoassay for prostatic acid phosphatase.
    Cooper JF; Foti AG
    Natl Cancer Inst Monogr; 1978 Dec; (49):235-7. PubMed ID: 748776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A preliminary report of mitotane therapy of advanced renal and prostate cancer.
    Hogan TF; Citrin DL; Freeberg BL
    Cancer Treat Rep; 1981; 65(5-6):539-40. PubMed ID: 7237479
    [No Abstract]   [Full Text] [Related]  

  • 27. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contribution on the clinical aspects of prostatic carcinoma].
    Sladczyk E
    Z Arztl Fortbild (Jena); 1967 Jul; 61(13):657-60. PubMed ID: 5598256
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study of cancer of the prostate. In vitro culture of human prostatic tissue. Trans-rectal aspiration cytology and determination of DNA levels using cytophotometry in prostatic cancer. Radio-immunologic determination of acid phosphatases].
    Bouffioux C
    Acta Urol Belg; 1982; 50(4):397-544. PubMed ID: 7168426
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study.
    Qazi R; Khandekar J
    Am J Clin Oncol; 1983 Apr; 6(2):203-5. PubMed ID: 6681933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation therapy in the management of localized carcinoma of the prostate: a preliminary report.
    McGowan DG
    Cancer; 1977 Jan; 39(1):98-103. PubMed ID: 401678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leuco-erythroblastic anaemia in prostatic cancer. Report of two cases with complete haematological remission.
    Eriksson S; Killander J; Wadman B
    Scand J Haematol; 1972; 9(6):648-53. PubMed ID: 4644425
    [No Abstract]   [Full Text] [Related]  

  • 33. Prolaction and prostate cancer.
    Farnsworth WE; Gonder MJ
    Urology; 1977 Jul; 10(1):33-4. PubMed ID: 878120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Increase in acid phosphatases and their labile tartrate fraction in a nonprostatic metastatic cancer].
    Coindre JM; Goussot JF; De Mascarel A
    Presse Med; 1984 Mar; 13(11):683. PubMed ID: 6231570
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Jones WG; Fosså SD; Verbaeys AC; Droz JP; Klijn JG; Boven E; de Pauw M; Sylvester R
    Eur J Cancer; 1990; 26(5):646. PubMed ID: 2144757
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrogenesis imperfecta ossium: remission with melphalan.
    Stamp TC; Byers PD; Ali SY; Jenkins MV; Willoughby JM
    Lancet; 1985 Mar; 1(8428):582-3. PubMed ID: 2857933
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pop the Champagne].
    Nordby OP
    Tidsskr Nor Laegeforen; 2012 Jan; 132(1):11. PubMed ID: 22240816
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
    Smith DC; Jodrell DI; Egorin MJ; Ambinder RM; Zuhowski EG; Kreis W; Ellis PG; Trump DL
    Cancer Chemother Pharmacol; 1993; 31(5):363-8. PubMed ID: 7679331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melphalan in metastatic cancer of the prostate: a pilot study.
    Franks CR
    Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.